You are here

peanut allergy

Food allergy biotech DBV is running out of cash, with phase 3 trials underway

Fierce Biotech

Fri, 03/8/24 - 11:32 am

DBV Technologies

clinical trials

Novartis Ends Phase III Peanut Allergy Trial in Another Flop for Potential Xolair Successor

BioSpace

Thu, 01/18/24 - 10:58 am

clinical trials

Years after $2B buyout, Nestlé ditches Aimmune's peanut allergy drug Palforzia

Fierce Pharma

Tue, 09/5/23 - 11:32 am

Stallergenes Greer

Trial investigating peanut allergy immunotherapy hits final milestone

Clinical Trials Arena

Wed, 07/26/23 - 11:34 am

Intrommune Therapeutics

clinical trials

IgGenix sprints to clinic with peanut allergy candidate and additional $40M

Endpoints

Mon, 02/6/23 - 06:15 pm

Nestlé to Sell Off Peanut Allergy Treatment, Not the Blockbuster They Hoped

Motley Fool

Tue, 11/29/22 - 11:00 pm

Aimmune Therapeutics

FDA slaps hold on DBV peanut allergy trial in call for protocol changes

Fierce Biotech

Thu, 09/22/22 - 10:33 am

DBV Technologies

clinical trials

DBV patches up prospects with phase 3 win in infants with peanut allergies

Fierce Biotech

Wed, 06/8/22 - 10:15 am

DBV Technologies

clinical trials

NICE backs Aimmune’s peanut allergy drug Palforzia for children

Pharmaforum

Mon, 12/27/21 - 11:14 am

Angany Partners with Mass General on Potential Peanut Allergy Vaccine

BioSpace

Wed, 11/10/21 - 10:44 am

FDA Accepts Investigational New Drug Application for Peanut Allergy Candidate Developed by COUR Pharmaceuticals

Drugs.com

Thu, 09/16/21 - 10:42 pm

Cour Pharmaceuticals

clinical trials

Leaps by Bayer backs a protein engineering startup taking on Aimmune — and Nestlé — in peanut allergy

Endpoints

Wed, 01/27/21 - 11:29 am

DBV restructuring claims 200 jobs as it beats out a path toward peanut patch OK

Endpoints

Thu, 01/7/21 - 11:21 pm

DBV Technologies

Allergy Therapeutics launches biomarker study of peanut allergy vaccine candidate

Pharma Times

Wed, 01/6/21 - 11:20 pm

Allergy Therapeutics

Why DBV Technologies Stock Is Soaring Today

Motley Fool

Mon, 11/2/20 - 11:04 pm

DBV Technologies

The central figure in Nestlé's $2.6B Aimmune buyout? Covid-19

Endpoints

Tue, 09/15/20 - 11:01 am

Nestle pays $2 billion to secure Aimmune’s allergy treatment

CNBC

Mon, 08/31/20 - 10:54 am

Viaskin™ Peanut’s Long-Term Phase III Updates and What the FDA Has to Say About Them

BioSpace

Fri, 08/14/20 - 11:03 am

DBV Technologies

With Peanut Patch in FDA Purgatory, DBV Plans Layoffs to Stretch Cash

Xconomy

Fri, 06/26/20 - 07:50 pm

DBV Technologies

A Tale of 2 Biotechs With Competing Peanut Allergy Treatments

Motley Fool

Thu, 04/16/20 - 11:43 pm

DBV Technologies

Aimmune Therapeutics

Pages